But regulations remain unclear for companies that supply treatments.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regenerative medicine in China: main progress in different fields
Military Medical Research Open Access 19 August 2016
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Related external links
Ministry of Health/Announcement of new regulations (in Chinese)
Rights and permissions
About this article
Cite this article
Cyranoski, D. Stem-cell therapy faces more scrutiny in China. Nature 459, 146–147 (2009). https://doi.org/10.1038/459146a
Published:
Issue Date:
DOI: https://doi.org/10.1038/459146a
This article is cited by
-
Regenerative medicine in China: main progress in different fields
Military Medical Research (2016)
-
Chinese Newspaper Coverage of (Unproven) Stem Cell Therapies and their Providers
Stem Cell Reviews and Reports (2013)
-
The unregulated commercialization of stem cell treatments: a global perspective
Frontiers of Medicine (2011)
-
Order from chaos
Nature (2010)
-
Stem-cell laws in China fall short
Nature (2010)
